Stocktoria
USANA HEALTH SCIENCES INC USNA
USANA HEALTH SCIENCES INC (USNA) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2026 revenue was $925.3M at a 1.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.215 |
| Retained earnings / assets | 0.627 |
| EBIT / assets | 0.05 |
| Equity / liabilities | 3.403 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| USNA | USANA HEALTH SCIENCES INC | 6/9 | 7.37 | 32.6 | +8.3% |
| TLRY | Tilray Brands, Inc. | 4/9 | -11.01 | — | +11.5% |
| TRLV | Trulieve Cannabis Corp. | 4/9 | 1.09 | — | -0.4% |
| CRLBF | Cresco Labs Inc. | 3/9 | -2.99 | — | -9.5% |
| AAWH | Ascend Wellness Holdings, Inc. | 4/9 | -1.32 | — | -10.9% |
| CGC | Canopy Growth Corp | 4/9 | — | — | +10.5% |
| JUSHF | Jushi Holdings Inc. | 3/9 | -4.96 | — | +2.1% |
About USANA HEALTH SCIENCES INC
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. It operates in two segments, Core nutritional and Hiya Direct-To-Consumer. The company offers USANA nutritional optimizers, including supplements for cardiovascular health, skeletal/structural health, and digestive health; Essentials/CellSentials, such as vitamin and mineral supplements for age group beginning with children 13 months of age; and food products that include meal replacement shakes, snack bars, and other related products for healthy weight management, digestive health, and energy and hydration. It offers Celavive, a skincare regimen for various skin care types and ethnicities; and all other products comprising materials and online tools for associates to build business and marketing of products The company sells its products through retail customers, a subscription model, and direct selling, as well as online. The company was founded in 1992 and is headquartered in Salt Lake City, Utah.
FAQ
Is USNA financially healthy?
USANA HEALTH SCIENCES INC's Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does USNA pay a dividend?
No, USANA HEALTH SCIENCES INC does not currently pay a dividend.
How profitable is USNA?
In FY2026, USANA HEALTH SCIENCES INC had a net margin of 1.2% and a return on equity of 2.0%.
Is USNA overvalued or undervalued?
USANA HEALTH SCIENCES INC trades at about 23.3× trailing earnings — above its 10-year norm (10-year range 14.0×–37.4×, median 16.3×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for USNA?
The average Wall-Street price target for USANA HEALTH SCIENCES INC is $39.00, about 188.0% above the recent price, from 1 analysts.
Is USNA a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on USANA HEALTH SCIENCES INC: a Piotroski F-score of 6/9, an Altman Z″ in the safe zone, a P/E of about 32.6×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2026-01-03. Facts plus Stocktoria's own computed scores — not investment advice.